RHOA and cancer: Recently, we revealed that RHOA mutations contribute to cancer cell survival and cell migration through their dominant negative effect on the Rho-associated kinase (ROCK) pathway (10), but little is understood of how these functions are related to the clinicopathological features of DGC.